614 related articles for article (PubMed ID: 28043732)
1. Interactions between cannabidiol and Δ
Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
[TBL] [Abstract][Full Text] [Related]
2. Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.
Todd SM; Arnold JC
Br J Pharmacol; 2016 Jan; 173(1):53-65. PubMed ID: 26377899
[TBL] [Abstract][Full Text] [Related]
3. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
4. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.
Taffe MA; Creehan KM; Vandewater SA
Br J Pharmacol; 2015 Apr; 172(7):1783-91. PubMed ID: 25425111
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System.
Norris C; Loureiro M; Kramar C; Zunder J; Renard J; Rushlow W; Laviolette SR
Neuropsychopharmacology; 2016 Nov; 41(12):2839-2850. PubMed ID: 27296152
[TBL] [Abstract][Full Text] [Related]
9. Interactions between THC and cannabidiol in mouse models of cannabinoid activity.
Varvel SA; Wiley JL; Yang R; Bridgen DT; Long K; Lichtman AH; Martin BR
Psychopharmacology (Berl); 2006 Jun; 186(2):226-34. PubMed ID: 16572263
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.
Gomes FV; Issy AC; Ferreira FR; Viveros MP; Del Bel EA; Guimarães FS
Int J Neuropsychopharmacol; 2014 Oct; 18(5):. PubMed ID: 25618402
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.
Klein C; Karanges E; Spiro A; Wong A; Spencer J; Huynh T; Gunasekaran N; Karl T; Long LE; Huang XF; Liu K; Arnold JC; McGregor IS
Psychopharmacology (Berl); 2011 Nov; 218(2):443-57. PubMed ID: 21667074
[TBL] [Abstract][Full Text] [Related]
12. Delta-9-tetrahydrocannabinol potentiates fear memory salience through functional modulation of mesolimbic dopaminergic activity states.
Fitoussi A; Zunder J; Tan H; Laviolette SR
Eur J Neurosci; 2018 Jun; 47(11):1385-1400. PubMed ID: 29776015
[TBL] [Abstract][Full Text] [Related]
13. Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.
Lazenka MF; Tomarchio AJ; Lichtman AH; Greengard P; Flajolet M; Selley DE; Sim-Selley LJ
J Pharmacol Exp Ther; 2015 Sep; 354(3):316-27. PubMed ID: 26099530
[TBL] [Abstract][Full Text] [Related]
14. Female but not male rats show biphasic effects of low doses of Δ
Salviato BZ; Raymundi AM; Rodrigues da Silva T; Salemme BW; Batista Sohn JM; Araújo FS; Guimarães FS; Bertoglio LJ; Stern CA
Neuropharmacology; 2021 Sep; 196():108684. PubMed ID: 34181978
[TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
[TBL] [Abstract][Full Text] [Related]
17. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
Freeman AM; Petrilli K; Lees R; Hindocha C; Mokrysz C; Curran HV; Saunders R; Freeman TP
Neurosci Biobehav Rev; 2019 Dec; 107():696-712. PubMed ID: 31580839
[TBL] [Abstract][Full Text] [Related]
18. Absence of interaction between delta9-tetrahydrocannabinol (delta-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice.
Ham MT; De Jong Y
Psychopharmacologia; 1975; 41(2):169-74. PubMed ID: 1171491
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
[TBL] [Abstract][Full Text] [Related]
20. Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption.
Stern CA; Gazarini L; Vanvossen AC; Zuardi AW; Galve-Roperh I; Guimaraes FS; Takahashi RN; Bertoglio LJ
Eur Neuropsychopharmacol; 2015 Jun; 25(6):958-65. PubMed ID: 25799920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
